Download PDF
Dtsch Med Wochenschr 2005; 130(9): 461-465
DOI: 10.1055/s-2005-863076
Übersichten
Pneumologie
© Georg Thieme Verlag Stuttgart · New York

Pneumokokken-Schutzimpfung bei obstruktiven Lungenerkrankungen - Was können wir erwarten?

Pneumococcal vaccination in obstructive airway diseases - what can we expect?M. Rose1 , H. Lode2 , A. de Roux2 , S. Zielen1
  • 1Kinderklinik der JW Goethe Universität, Pneumologie und Allergologie, Frankfurt
  • 2Helios Klinikum Emil von Behring, Lungenklinik Heckeshorn, Berlin
Further Information

Publication History

eingereicht: 29.10.2004

akzeptiert: 18.2.2005

Publication Date:
24 February 2005 (online)

Also available at
   Permissions and Reprints
Preview

Zusammenfassung

Die Leitlinien vieler Länder empfehlen Pneumokokken-Schutzimpfungen für Patienten mit obstruktiven Lungenkrankheiten. Diese Arbeit gibt eine Übersicht zur Immunogenität und Sicherheit dieser Maßnahme. Es gibt keine Evidenz für eine nennenswerte Beeinträchtigung oder Gefährdung dieser Patienten durch eine Pneumokokken-Schutzimpfung. Wenige Arbeiten haben sich mit der Bedeutung der Pneumokokken-Schutzimpfung für die Vermeidung von Exazerbationen obstruktiver Lungenkrankheiten befasst. Vorhandene Studien haben diese Fragestellung meist nur als Nebenaspekt untersucht. Die Ergebnisse sind im Kindes- wie Erwachsenenalter imkohärent. Da jedoch die Konjugatvakzine Kinder unter 5 Jahren zusätzlich effektiv vor lebensbedrohlichen invasiven Infektionen schützt, und bei gesunden Erwachsenen bakteriämischen Pneumonien durch die Polysaccharidvakzine vorgebeugt wird, erscheint der Einsatz bei chronisch lungenkranken Patienten gerechtfertigt.

Summary

Many countries’ guidelines recommend pneumococcal vaccination for patients suffering from obstructive airway disease. This paper reviews the literature as to immunogenicity and safety of this immunization. There is no evidence for a negative effect of pneumococcal vaccination on these patients. Only a few data exist on the preventive impact of pneumococcal vaccination as to exacerbations of obstructive airway diseases. Existing studies mostly took up this question as a side aspect. The effect in children and adults appears limited. On the other hand, the pneumococcal conjugate vaccine prevents life-threatening invasive infections in children younger than 5 years, and pneumococcal polysaccharide vaccine protects healthy adults against bacteriaemic pneumonia. Thus, pneumococcal vaccination of patients suffering from obstructive airway disease is recommendable.

Literatur

  • 1 Black S, Shinefield H, Fireman B. et al. Northern California Kaiser Permanente Vaccine Study Center Group . Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.  Pediatr Infect Dis J. 2000;  19 187-195
    Search in Google Scholar
  • 2 Black S, Shinefield H. Safety and efficacy of the seven valent pneumococcal conjugate vaccine: evidence from Northern California.  Eur J Pediatr. 2002;  161 127-131
    Search in Google Scholar
  • 3 Black S B, Shinefield H R, Ling S. et al . Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.  Pediatr Inf Dis J. 2002;  21 810-815
    Search in Google Scholar
  • 4 Bogaert D, van der Valk P, Ramdin R. et al . Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease.  Infect Immun. 2004;  72 818-823
    Search in Google Scholar
  • 5 Christensen B, Hedlund J, Lundberg P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.  Eur Respir J. 2004;  23 363-368
    Search in Google Scholar
  • 6 Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.  Pediatric Infect Dis J. 2003;  22 532-540
    Search in Google Scholar
  • 7 Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.  Pediatr Infect Dis J. 1997;  16 1060-1064
    Search in Google Scholar
  • 8 Davies L, Hardcroft Mutton K, Earis J E, Kennedy N J. Antimicrobial management of acute exacerbation of chronic airflow limitation.  QJM. 2001;  94 373-378
    Search in Google Scholar
  • 9 Davis L D, Fireman B, Shinefield H R. Pneumococcal Conjugate Vaccine in Children.  NEJM. 2004;  350 84-85
    Search in Google Scholar
  • 10 De Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenity of the 23-valent Pneumococcal Polysaccharide Vaccine in COPD Patients. 2004 akzeptiert für respiratory medicine
    Search in Google Scholar
  • 11 EMEA .Commission Decision amending the marketing authorization for the medicinal product for human use „Prevenar - Pneumococcal saccharide conjugated vaccine, adsorbed”,. EU/1/00/167/001 - 007, (EMEA/H/C/323/II/18) Var 18 type II 2004
    Search in Google Scholar
  • 12 Evans H E, Mandel I, Glass L. Serum enzyme inhibitors, immunoglobulins, and upper respiratory tract bacteria in asthma.  Am Rev Respir Dis. 1973;  108 672-675
    Search in Google Scholar
  • 13 Fine M J, Smith M A, Carson C A. et al . Efficacy of pneumococcal vaccination in adults.  Arch Intern Med. 1994;  154 2666-2677
    Search in Google Scholar
  • 14 Fletcher T J, Tunnicliffe W S, Hammond K, Roberts K, Ayres J G. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease.  BMJ. 1997;  314 1663-1666
    Search in Google Scholar
  • 15 Gratten M, Morey F, Dixon J. et al . An outbreak of serotype 1 Streptococcus pneumoniae infection in central Australia.  Med J Aust. 1993;  158 340-342
    Search in Google Scholar
  • 16 Haby M M, Peat J K, Marks G B, Woolcock A J, Leeder S R. Asthma in preschool children: prevalence and risk factors.  Thorax. 2001;  56 589-595
    Search in Google Scholar
  • 17 Hausdorff W P, Bryant J, Kloek C, Paradiso P R, Siber G R. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use.  Clin Infect Dis. 2000;  30 100-140
    Search in Google Scholar
  • 18 Hess T. Pneumococcal vaccination: yes or no?.  Schweiz Med Wochenschr. 1998;  128 1096-1103
    Search in Google Scholar
  • 19 ISAAC . The international study of asthma and allergies in childhood Steering Committee. Worldwide variation in prevalence of asthma, allergic rhinoconjunctivitis, and atopic eczema.  Lancet. 1998;  351 1225-1232
    Search in Google Scholar
  • 20 Klugman K P, Madhi S A, Huebner R E, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.  NEJM. 2003;  349 1341-1348
    Search in Google Scholar
  • 21 Lahhod N, Emerson S S, Kumar P, Sorensen R U. Antibiotic levels and response to pneumococcal vaccine in steroid-dependent asthma.  Ann Allergy. 1993;  70 289-294
    Search in Google Scholar
  • 22 Lee H J, Kang J H, Henrichsen J. et al . Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and children at increased risk of pneumococcal infection.  Vaccine. 1995;  13 1533-1538
    Search in Google Scholar
  • 23 Lehmann D, Marshall T F, Riley I D, Alpers M P. Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections in Papua New Guinean children.  Ann Trop Paediatr. 1991;  11 247-257
    Search in Google Scholar
  • 24 Madhi S A, Klugman K P. A role for Streptococcus pneumoniae in virus-associated pneumonia.  Nature Medicine. 2004;  10 811-813
    Search in Google Scholar
  • 25 Marfan A A, Sporrer J, Moore P S, Siefkin A D. Risk factors for adverse outcomes in persons with pneumococcal pneumonia.  Chest. 1995;  107 457-462
    Search in Google Scholar
  • 26 Mbelle N, Huebner R E, Wasas A D, Kimura A, Chang I, Klugman K P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.  J Infect Dis. 1999;  180 1171-1176
    Search in Google Scholar
  • 27 Melegaro A, Edmunds J. The 23-valent pneumococcal polysaccharide vaccine: Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses.  Europ J Epidemiol. 2004;  19 353-363
    Search in Google Scholar
  • 28 Moore R A, Wiffen P J, Lipsky B A. Are the pneumococcal polysaccharide vaccines effective? Meta analysis of the prospective trials.  BMC Family Practice. 2000;  1 1471-2296
    Search in Google Scholar
  • 29 Obaro S, Adegbola R A, Banya W A, Greenwood B M. Carriage of pneumococci after pneumococcal vaccination.  Lancet. 1996;  348 271-272
    Search in Google Scholar
  • 30 Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines.  J Med Microbiol. 2002;  51 98-104
    Search in Google Scholar
  • 31 O’Brien K L, Swift A J, Winkelstein J A. et al. Pneumococcal Conjugate Vaccine Study Group . Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease.  Pediatrics. 2000;  106 965-972
    Search in Google Scholar
  • 32 Pelton S I, Klein J O. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children.  Pediatrics. 2002;  110 805-814
    Search in Google Scholar
  • 33 Reinert R R, Kaufhold A, Schlaeger J J, Meschery V, Lütticken R. Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae isolates causing systemic infections among children in Germany, 1992 to 1996.  Pediatr Infect Dis J. 1997;  16 244-245
    Search in Google Scholar
  • 34 Riley I D, Lehmann D, Alpers M P, Marshall T F, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.  Lancet. 1986;  2 877-881
    Search in Google Scholar
  • 35 Rose M, Hey C, Kujumdshiev S, Gall V, Schubert R, Zielen S. Immunogenicity of pneumococcal vaccination of patients with cochlear implants.  J Infect Dis. 2004;  190 551-557
    Search in Google Scholar
  • 36 Rose M, Hey C, Kujumdshiew S, Gall V, Zielen S. Gefahr der bakteriellen Meningitis.  Dtsch Ärztebl. 2004;  101 1072-1074
    Search in Google Scholar
  • 37 Schuller N. Prophylaxis of otitis media in asthmatic children.  Pediatr Infect Dis. 1983;  2 280-283
    Search in Google Scholar
  • 38 STIKO . Aktuelle Impfempfehlungen: Pneumokokken.  Epidemiol Bull. 2004; 
    Search in Google Scholar
  • 39 Vernacchio L, Neufeld E, MacDonald K. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young aduls with sickle cell disease.  J Pediatr. 1998;  133 275-278
    Search in Google Scholar
  • 40 von Kries R, Hermann M, Hachmeister A. et al . Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children.  Pediatr Infect Dis J. 2002;  21 1017-1023
    Search in Google Scholar
  • 41 Whitney C G, Klugman K P. Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine.  Semin Pediatr Infect Dis. 2004;  15 86-93
    Search in Google Scholar
  • 42 WHO . Pneumococcal vaccines.  Weekly Epidemiology Records. 1999;  74 177-183
    Search in Google Scholar
  • 43 Worth H, Buhl R, Cegla U. et al . Guidelines for the diagnosis and treatment of chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie.  Pneumologie. 2002;  56 704-738
    Search in Google Scholar
  • 44 Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.  Infect Immun. 2000;  68 1435-1440
    Search in Google Scholar
  • 45 Fiore A E, Levine O S, Elliott J A, Facklam R R, Butler J C. Effectiveness of Pneumococcal Polysaccharide Vaccine for Preschool-Age Children with Chronic Disease.   Energy Infect Dis. 1999;  5(6) 828-831
    Search in Google Scholar

Dr. med. Markus Rose

Zentrum der Kinderheilkunde und Jugendmedizin, Pneumologie und Allergologie, J. W. Goethe Universität

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Phone: 069/63015754

Email: Markus.Rose@kgu.de